# A Phase 3 Study of NTLA-2001 in ATTRv-PN

> **NCT06672237** · PHASE3 · RECRUITING · sponsor: **Intellia Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Neuromuscular Disease
- Neuromuscular Diseases (NMD)
- Neurodegenerative Disease
- Neurodegenerative Disease, Hereditary
- Neurodegenerative Diseases
- Neuromuscular Diseases
- Nerve Disorders
- Nervous System Disease
- Nervous System Diseases
- Genetic Disease, Inborn
- Amyloidosis, Familial
- Amyloidosis, Hereditary
- Amyloidosis
- Polyneuropathies
- Amyloid Neuropathies
- Amyloid Neuropathies, Familial
- Peripheral Nervous System Disease
- Peripheral Nervous System Diseases
- Metabolism, Inborn Errors
- Metabolic Diseases

## Interventions

- **BIOLOGICAL:** nexiguran ziclumeran
- **DRUG:** Normal Saline as Placebo

## Key facts

- **NCT ID:** NCT06672237
- **Lead sponsor:** Intellia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-22
- **Primary completion:** 2027-07
- **Final completion:** 2028-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672237, "A Phase 3 Study of NTLA-2001 in ATTRv-PN". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06672237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*